{"id":1738,"date":"2018-12-16T06:28:23","date_gmt":"2018-12-16T06:28:23","guid":{"rendered":"https:\/\/crigroup.com\/?post_type=case-study&p=1738"},"modified":"2022-03-30T08:40:13","modified_gmt":"2022-03-30T08:40:13","slug":"pharma-due-diligence","status":"publish","type":"case-study","link":"https:\/\/crigroup.com\/ar\/case-study\/pharma-due-diligence\/","title":{"rendered":"Major Pharma conducts due diligence investigation: lessons learned"},"content":{"rendered":"

UNETHICAL PRACTICES, CONFLICT OF INTEREST, BRIBERY, AND CORRUPTION DISCOVERED AMONG A RANGE OF EMPLOYEES <\/strong>AT MAJOR PHARMA COMPANY, EVEN THE CFO WAS ON THE TAKE –<\/em><\/p>\n

A major pharmaceutical company engaged CRI Group to conduct an integrity due diligence and conflict of interest investigation. The focus of the action was to uncover unethical practices, including bribery and corruption, by senior employees. The client\u2019s corporate security department had received conflict of interest complaints that reportedly involved a range of employees, from sales personnel on up to the chief financial officer (CFO).<\/p>\n

This ebook examines the following:<\/p>\n